Your browser doesn't support javascript.
loading
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
Moreira, Andre L; Ocampo, Paolo S S; Xia, Yuhe; Zhong, Hua; Russell, Prudence A; Minami, Yuko; Cooper, Wendy A; Yoshida, Akihiko; Bubendorf, Lukas; Papotti, Mauro; Pelosi, Giuseppe; Lopez-Rios, Fernando; Kunitoki, Keiko; Ferrari-Light, Dana; Sholl, Lynette M; Beasley, Mary Beth; Borczuk, Alain; Botling, Johan; Brambilla, Elisabeth; Chen, Gang; Chou, Teh-Ying; Chung, Jin-Haeng; Dacic, Sanja; Jain, Deepali; Hirsch, Fred R; Hwang, David; Lantuejoul, Sylvie; Lin, Dongmei; Longshore, John W; Motoi, Noriko; Noguchi, Masayuki; Poleri, Claudia; Rekhtman, Natasha; Tsao, Ming-Sound; Thunnissen, Erik; Travis, William D; Yatabe, Yasushi; Roden, Anja C; Daigneault, Jillian B; Wistuba, Ignacio I; Kerr, Keith M; Pass, Harvey; Nicholson, Andrew G; Mino-Kenudson, Mari.
Afiliación
  • Moreira AL; Department of Pathology, New York University Langone Health, New York, New York. Electronic address: andre.moreira@nyumc.org.
  • Ocampo PSS; Department of Pathology, New York University Langone Health, New York, New York.
  • Xia Y; Department of Biostatistics, New York University Langone Health, New York, New York.
  • Zhong H; Department of Biostatistics, New York University Langone Health, New York, New York.
  • Russell PA; Department of Pathology, St. Vincent's Hospital, Victoria, Australia.
  • Minami Y; Department of Pathology, Ibarakihigashi National Hospital, Tokai, Japan.
  • Cooper WA; Department of Pathology, Royal Prince Alfred Hospital, Camperdown, Australia.
  • Yoshida A; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Bubendorf L; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland.
  • Papotti M; Department of Oncology, University of Turin, Turin, Italy.
  • Pelosi G; Department of Pathology, University of Milan, Milan Italy; IRCCS MultiMedica, Milan Italy.
  • Lopez-Rios F; Pathology-Laboratorio de Dianas Terapeuticas, HM Hospitales, Madrid, Spain.
  • Kunitoki K; Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Ferrari-Light D; Department of Surgery, New York University Langone Health, New York, New York.
  • Sholl LM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Beasley MB; Department of Pathology, Icahn School of Medicine, Mount Sinai Health System, New York, New York.
  • Borczuk A; Department of Pathology, Weill Cornell Medicine, New York, New York.
  • Botling J; Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden.
  • Brambilla E; Department of Anatomic Pathology and Cytology, Université Grenoble Alpes, Grenoble, France.
  • Chen G; Department fo Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Chou TY; Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Chung JH; Department of Pathology, Seoul National University Bundang Hospital, Seoul, South Korea.
  • Dacic S; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Jain D; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • Hirsch FR; Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York.
  • Hwang D; Department of Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Lantuejoul S; Department fo Pathology, Centre Léon Bérard Unicancer, Lyon, France.
  • Lin D; Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
  • Longshore JW; Carolinas Pathology Group, Atrium Health, Charlotte, North Carolina.
  • Motoi N; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Noguchi M; Department of Pathology, University of Tsukuba, Tsukuba, Japan.
  • Poleri C; Office of Pathology Consultants, Buenos Aires, Argentina.
  • Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Tsao MS; University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Thunnissen E; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
  • Travis WD; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yatabe Y; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Roden AC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Daigneault JB; International Association for the Study of Lung Cancer, Aurora, Colorado.
  • Wistuba II; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kerr KM; Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
  • Pass H; Department of Surgery, New York University Langone Health, New York, New York.
  • Nicholson AG; Department of Pathology, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
J Thorac Oncol ; 15(10): 1599-1610, 2020 10.
Article en En | MEDLINE | ID: mdl-32562873
INTRODUCTION: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with prognosis aimed at establishing a grading system for invasive pulmonary adenocarcinoma. METHODS: A multi-institutional study involving multiple cohorts of invasive pulmonary adenocarcinomas was conducted. A cohort of 284 stage I pulmonary adenocarcinomas was used as a training set to identify histologic features associated with patient outcomes (recurrence-free survival [RFS] and overall survival [OS]). Receiver operating characteristic curve analysis was used to select the best model, which was validated (n = 212) and tested (n = 300, including stage I-III) in independent cohorts. Reproducibility of the model was assessed using kappa statistics. RESULTS: The best model (area under the receiver operating characteristic curve [AUC] = 0.749 for RFS and 0.787 for OS) was composed of a combination of predominant plus high-grade histologic pattern with a cutoff of 20% for the latter. The model consists of the following: grade 1, lepidic predominant tumor; grade 2, acinar or papillary predominant tumor, both with no or less than 20% of high-grade patterns; and grade 3, any tumor with 20% or more of high-grade patterns (solid, micropapillary, or complex gland). Similar results were seen in the validation (AUC = 0.732 for RFS and 0.787 for OS) and test cohorts (AUC = 0.690 for RFS and 0.743 for OS), confirming the predictive value of the model. Interobserver reproducibility revealed good agreement (k = 0.617). CONCLUSIONS: A grading system based on the predominant and high-grade patterns is practical and prognostic for invasive pulmonary adenocarcinoma.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article